IONS' shares fell after announcing the pricing of its secondary issue of shares, which were at a 12% discount to the previous closing price.

Analyst Etzer Darout of BMO Capital maintained a Hold rating on Novartis (NVS – Research Report), retaining the price target of $118.00.

Novartis and GSK are its partners for pelacarsen and bepirovirsen, respectively. While the GSK-partnered drug is being developed in two late-stage studies for chronic hepatitis B (CHB), the ...

such as the expected pelacarsen readout. The reaffirmed Market Perform rating and price target suggest a steady outlook for Novartis shares according to BMO Capital's analysis. In other recent ...

Pelacarsen sodium is under clinical development by Novartis and currently in Phase III for Cardiovascular Disease. According to GlobalData, Phase III drugs for Cardiovascular Disease have a 38% phase ...

While Novartis has a number of promising pipeline products—such as Cosentyx, pelacarsen, ianalumab, and Pluvicto—key data releases and potential approvals for these drugs are not expected to ...

It will need to move quickly to try to catch Novartis and its development partner Akcea – an affiliate of Ionis – which are developing an antisense-based candidate called pelacarsen (formerly ...

It is playing catch-up with a rival Lp(a) targeting antisense drug from Novartis and development partner Akcea, called pelacarsen, which is already in a phase 3 trial called HORIZON with major ...

The revenue for Pelacarsen Sodium is expected to reach an annual total of $269 mn by 2035 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are ...

The analyst highlighted the early adoption of key Novartis products, such as Kisqali, Scemblix, and Pluvicto, as significant drivers of the stock's recent momentum. Moreover, the anticipated positive ...